All News
Fukui et al. Retrospective study of alternate day steroids in IgG4-RD. No difference in flares. Significantly lower Glucocorticoid toxicity index -29.5 at 12 months -20 at 24 months. Not convinced until I see stronger data! @rheumnow #ACR22 Abstr#0128 https://t.co/20K4dKXE7R https://t.co/X4kJgCqhAE
Richard Conway RichardPAConway ( View Tweet)
Maguire et al @Sineadm15 @bososhea Stronger relationship between disease activity and QoL in men than women with AxSpA. Our current tools may be inadequate to fully evaluate women with AxSpA @rheumnow #ACR22 Abstr#0406 https://t.co/duHqO0DXh3 https://t.co/yRcFiNpujT
Richard Conway RichardPAConway ( View Tweet)
Woody Palmer fasciitis? Think cancer (esp ovarian CA in women) #acr22 @rheumnow https://t.co/c6nCATfGxt
TheDaoIndex KDAO2011 ( View Tweet)
Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless of BMI, tofacitinib better than placebo.
BMI <25: more AE and SAE
Abs#0405 @RheumNow #ACR22 https://t.co/qs3U4mjUXD
Robert B Chao, MD doctorRBC ( View Tweet)
Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE
Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK
Robert B Chao, MD doctorRBC ( View Tweet)
Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, they had > TJC, > SJC, > Pso & > dactylitis.
Failure also w/: pain 24%, pso 15%, fatigue 12% and < ability to be active 9%.
https://t.co/dQseCNSDBS Abstr #0393 #ACR22 @Rheumnow https://t.co/kGlmscsKL7
Aurelie Najm AurelieRheumo ( View Tweet)
MACE and VTE from 9 (6 RA, 2 PsA, 1 AS) RCTs w/ UPA.
6000+ pts received UPA 40-50% w/ > or = 2 BL CV risk factors.
41 MACE UPA 15mg RA-PsA group & 2 fatal VTE UPA 15mg RA group.
Overlapping confidence intervals w/ADA & MTX.
https://t.co/7xtZlDIkVu
Abs#0510 #ACR22 @Rheumnow https://t.co/reywXk5Z0Z
Aurelie Najm AurelieRheumo ( View Tweet)
RECITAL trial comparing ritux vs cyclo for CTD-ILD. This is a sub-group analysis of larger trial. 1/n
@RheumNow #ACR22 #Plenary
Julian Segan JulianSegan ( View Tweet)
GPA is a rare cause of both submandibular gland enlargement and dacryoadenitis. Can look like IgG4RD and Sjogrens.
@RheumNow #ACR22 #Pearls https://t.co/Gw6OF4H2w2
Julian Segan JulianSegan ( View Tweet)
Are my patients represented in PsA trials? @RheumNow #ACR22
Abstract #0090; Ignite Talk
☝️Of 25 RCT from 2002-2022, only 13 included patients of non-White race
☝️Hispanic/Latinx ethnicity was reported in 0 studies
☝️Black individuals represented < 1% patients included
Catherine Sims, MD DrCassySims ( View Tweet)
Dr. John Stone pronounces GiACTA “GEE-ACTA”. I have been pronouncing it “GIA-ACTA” and will now correct myself #vasculitis #ACR22
Catherine Sims, MD DrCassySims ( View Tweet)
#ACR22 Year in Review. Dr Langford summarised significant progress attained in 2022 in combating #COVID and protect our immunosuppressed patients @RheumNow https://t.co/lZSDRj3bkm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Key points in managing MDA5+ DM
1. Monitor lungs - HRCT/PFTs
2. Test muscle endurance (ref: IMACS site) not just strength
3. Close observation
4. MTX/MMF initial treatments
5. Repeat muscle biopsy if diagnosis unclear
Meet the Expert Lundberg I, IMM session @RheumNow #ACR22 https://t.co/ZVFsYgDBx2
Dr. Antoni Chan synovialjoints ( View Tweet)
Key points in managing MDA5+ DM
1. Consider Tofacitinib 5-10mg bd
2. Low to mid dose Prednisolone 20-30mg tapering
3. Other Rx: Tacrolimus, IVIG
4. Poor prognostic factors: lymphopenia, raised ferritin, old age, rapid ILD progression
Wang GC, IIM session @RheumNow #ACR22 https://t.co/UF2PjAg0Mw
Dr. Antoni Chan synovialjoints ( View Tweet)
Therapies for AS and nr-AxSpA are coming together. Both AS and nr-AxSpA present with similar burden of disease. TNFi, IL-17i and JAKi now approved for use in nr-AxSpA.
Jose U Scher, SpA Review @RheumNow #ACR22 https://t.co/vcHcd7OyAU
Dr. Antoni Chan synovialjoints ( View Tweet)
Mimics of Sjogren’s Syndrome @RheumNow #ACR22 https://t.co/nEAXKb6qF0
Dr. Antoni Chan synovialjoints ( View Tweet)
“The Stone Age did not end because of a shortage of stones. We need new solutions to our problems” Abraham Verghese. Amazing insight into our challenges in clinic today at the #ACR22 opening session @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
GCA Fast Track clinics are nice - but usually need specialized ultrasound.
What if you don't have it? (also, COVID?)
@PennRheum implemented *without* ultrasound
Excellent outcomes
The early referral triage makes all the difference. Knowledge is power ABST0463 #ACR22 @RheumNow https://t.co/rjkVERW559
David Liew drdavidliew ( View Tweet)
More details at https://t.co/4U8v7oeUYW
Enormously powerful in these times of rheumatology workforce shortage. I would love to see this in Australia and elsewhere - so much to learn. Congratulations to all involved, and thanks @ACRheum and @UCSF for supporting #ACR22
David Liew drdavidliew ( View Tweet)
Just published! QR code attached! #ACR22 @RheumNow https://t.co/lMD0mFoT4M
Patricia Harkins DrTrishHarkins ( View Tweet)